Investing.com - VistaGen Therapeutics (NASDAQ: VTGN) reported second quarter EPS of $-0.940, $0.08 worse than the analyst estimate of $-0.860. Revenue for the quarter came in at $170K versus the consensus estimate of $184.6K.
VistaGen Therapeutics's stock price closed at $7.510. It is up 75.300% in the last 3 months and up 59.150% in the last 12 months.
VistaGen Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See VistaGen Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, VistaGen Therapeutics's Financial Health score is "fair performance".
Check out VistaGen Therapeutics's recent earnings performance, and VistaGen Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar